** Shares of medical device maker NeuroPace NPCE.O fall 15% to $15.02 premarket
** Co, citing preliminary data, says neuromodulation therapy for a group of genetic epilepsy syndromes failed to meet main efficacy goal in the overall population in a 2-year study
** The device, RNS System, is implanted in the skull to constantly monitor brain waves, identifying and disrupting unusual activity that may trigger seizures
** The device, however, showed significant efficacy in a subset of patients, which represents the majority of participants - NPCE
** It is approved in the U.S. to treat focal epilepsy, a type of seizure that affects only one side of the brain and body
** Up to last close, stock up ~58% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。